Sex-Related Prognostic Predictors for Parkinson Disease Undergoing Subthalamic Stimulation

World Neurosurg. 2015 Oct;84(4):906-12. doi: 10.1016/j.wneu.2015.05.023. Epub 2015 May 30.

Abstract

Background: A few reports have addressed the sex-related efficacy of deep brain stimulation (DBS) in the subthalamic nucleus (STN) to treat advanced Parkinson disease (PD). The present study evaluates the sex-related prognostic factors for STN-DBS outcomes.

Methods: Seventy-two consecutive patients (48 men and 24 women) were reviewed retrospectively. Changes in the Unified PD Rating Scale scores were compared between men and women in the 6-month drug-off/DBS-on state relative to the preoperative drug-off baseline. A multivariate linear regression model was used to identify the preoperative factors predictive of motor improvements after surgery.

Results: Before surgery, the male and female patient groups were comparable in clinical severity, except the women were associated with slightly inferior cognition (P < 0.05) and a relatively better response to levodopa (LD) (P < 0.05) than the men. Both sexes showed similar clinical improvements after STN-DBS therapy. In men, preoperative lower LD requirement and higher motor dysfunction, particularly tremor (adjusted R(2) = 0.613, P < 0.001), as well as greater improvement in tremor and rigidity after LD therapy (adjusted R(2) = 0.232, P = 0.001) were favorable predictors of surgical outcomes. Women achieved a significant improvement if they performed well in activities of daily living even with higher baseline motor scores (adjusted R(2) = 0.620, P < 0.001), or exhibited improvements in akinesia disability after preoperative LD therapy (adjusted R(2) = 0.305, P = 0.003).

Conclusions: STN-DBS therapy is equally beneficial for both sexes. Sex-related differences exist with regard to favorable prognostic predictors for early surgical outcomes.

Keywords: Deep brain stimulation; Parkinson disease; Prognosis; Sex; Subthalamic nucleus.

MeSH terms

  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / therapeutic use
  • Cognition
  • Deep Brain Stimulation / methods*
  • Female
  • Humans
  • Levodopa / administration & dosage
  • Levodopa / therapeutic use
  • Male
  • Middle Aged
  • Movement Disorders / etiology
  • Movement Disorders / physiopathology
  • Neuropsychological Tests
  • Parkinson Disease / psychology
  • Parkinson Disease / surgery*
  • Postoperative Complications / epidemiology
  • Prognosis
  • Retrospective Studies
  • Sex Characteristics
  • Subthalamic Nucleus / surgery*
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Levodopa